The assurance of study subjects' privacy and confidentiality is fundamental to the enrollment of participants in clinical research. At the same time, the number of datapoints collected and commodified by the commercial world on each individual has increased exponentially. The potential overlap or convergence of these datastreams, whether intentional or inadvertent, threatens the promise of privacy. This session will explore the range and means of data collected in the pursuit of human research and the limits of protections possible in today's digital world.

CEU: 1.00 ACRP

Speaker:

• Robert Romanchuk, CIP, Chairperson, Univo IRB, Univo IRB

Watch a Sneak Peek into the Session Content:

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

We are experiencing serious shortfalls in the number of clinical research physicians (principal investigators) needed to keep the enterprise healthy, in part due to aging populations and to the aftereffects of restrictions and burnout from pandemic conditions. It is estimated that less than 5% of U.S. physicians are participating in clinical research at any given time. Is there a sustainable path to attracting and retaining new and returning physicians for conducting clinical studies? With approximately 70,000 clinical studies ongoing or planned, and 35% being U.S.-only, the challenge is to create a collective approach addressing the gap ahead. Sponsors, contract research organizations, site networks, and medical associations realized during the worst days of COVID-19 that collective minds create solutions. Engaging/involving more "research naïve" physicians is a key to success for stakeholders everywhere. Understanding what these physicians need is important. This panel will include physicians who are new to the principal investigator role. Why did they add clinical research to their patient-care services? What have they learned? Why have they continued in clinical research? Are their communities showing greater interest? What are their enrolled patients sharing with them about their experiences as participants?

CEU: 1.00 ACRP

Speakers:

• Edwin Burkett, MD, Chief Medical Officer, Alliance Medical Ministry

• Amir Herman, DO, Medical Director, East Northport Medical Care

• Nancy Sacco, PhD, VP Head of Clinical and Site Development Operations, SiteBridge Research Inc

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Study & Site Management Journey Sponsor

This session will provide a high-level overview of the emerging regulatory environment governing clinical research. With a new administration in the White House and recent and forthcoming updates to various U.S. Food and Drug Administration guidances, International Council for Harmonization guidelines, and more targeting ethical, safety, and efficacy concerns in the design and conduct of drug and device clinical trials, this is a session providing value for stakeholders across the entire clinical research enterprise.

CEU: 1.00 ACRP

Speaker:

• David Vulcano, LCSW, MBA, CIP, RAC, FACRP, VP Clinical Research Compliance & Integrity, HCA Healthcare

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Artificial intelligence (AI) and machine learning (ML) technologies are transforming healthcare delivery. Understanding the regulatory framework for study AI/ML utility, accuracy, efficacy, and reproducibility is key to the research process prior to its use in patient diagnosis and care. This is a cutting-edge topic upon which many new federal guidance documents have focused. It is often misunderstood by sponsors, sites, and investigators that if AI/ML is used for diagnosis, the technology it is FDA regulated. Operationally, the inclusion or exclusion of AI/ML findings into the electronic health record is poorly understood, although it is analogous to the 21 CFR 812 Investigational Device Exemption or 510 K pathway used for new laboratory testing procedures.

CEU: 1.00 ACRP

Speakers:

• Betty Donoval, Director, Research & Regulatory Affairs, Cook County Health

• Pamela Gonzalez, Manager Research Consultant, Huron LLC

Watch a Sneak Peek into the Session Content:

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Failure to understand and implement a comprehensive research billing compliance program can result in monetary penalties, close scrutiny from the U.S. Department of Health and Human Services' Office of Inspector General, and loss of reputation to a research institution. Institutions participating in clinical trials must understand the risks. Additionally, they need the knowledge and skills to accurately perform coverage analysis and manage charges based on that analysis. Finally, institutions need tools for conducting internal audits to ensure all processes are followed correctly. In this master class, participants will learn the “why” of having a comprehensive clinical research billing compliance program and can practice their coverage analysis and auditing skills through hands-on activities.

CEU: 1.00 ACRP

Speaker:

• Shanna Ford, MHA, Research Office Senior Associate, Huron Consulting Group

Watch a Sneak Peek into the Session Content:

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

An electronic data capture (EDC) system is software that’s used to electronically collect, manage, store, and export data for the clinical investigations which are critical to support safety and effectiveness claims for drugs, devices, and diagnostic tests. Most EDC systems can be customized to ensure data collection matches the product performance criteria, population characteristics, and statistical analysis plan for a product regulatory submission. This session will describe best practices and pitfalls to avoid when ensuring an EDC system is fit for each unique clinical investigation purpose. Let’s talk about the dos and don'ts and the collaborative sponsor/site/contract research organization approach to EDC validation to make sure we have a clean dataset with the most automated efficiencies and data mapping to scientific endpoints to achieve EDC that's fit for purpose every time.

CEU: 1.00 ACRP

Speaker:

• Patricia Smith, Senior Clinical Data Manager, NAMSA

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

The landscape of clinical trial design, conduct, and regulation continues to shift thanks to the rapid infusion of technology and an increased emphasis on inclusion and access. As a result, the U.S. Food and Drug Administration (FDA) and Congress are reevaluating their stances in a number of areas in order to further speed the path to healthcare innovation. However, these changes in policy can present operational challenges for sites and sponsors in the day-to-day management of trials and patient care. This session will run through the latest guidance changes and what they mean for sites and sponsors in 2025. Areas of focus will be the updated guidance on informed consent, diversity action plans, digital health technologies, decentralized clinical trials and Form FDA 1572 reform, use of real-world evidence, and changes to the FDA's Bioresearch Monitoring Program inspection processes. Additionally, the speakers will address the final ruling on taxing patient stipends, the Inflation Reduction Act, and the Food and Drug Omnibus Reform Act of 2022's mandate for innovation.

CEU: 1.00 ACRP

Speakers:

• Catherine Gregor, MBA, CCRP, CCRC, Chief Clinical Trial Officer, Florence Healthcare

• Sophia McLeod, Advocacy Advisor, Association of Clinical Research Organizations (ACRO)

Related Blog Content:

• Preparing for Changes at the FDA: Possible Impacts of a New Administration

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Study & Site Management Journey Sponsor

The future is here, and new technology available for investigational product (IP) management opens up a wide range of opportunities. In this session, we will provide an introduction to new IP temperature monitoring capabilities, cold chain innovation, digital automation, predictive analytics, and sustainable technologies that have the potential to enable enhanced quality and improve efficiency. We will also look at how new technologies at both the site and sponsor levels may support patient access to clinical trials and improve compliance with the tenets of ICH Good Clinical Practice.

CEU: 1.00 ACRP

Speakers:

• Liza Hill, BS, ACRP-CP, ACRP-PM, Associate Director, Clinical Operations - Clinical Research Manager, Infectious Disease (US), Merck

• Mary Williams, Associate Director, Clinical Operations, Merck

Watch a Sneak Peek into the Session Content:

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Study & Site Management Journey Sponsor

The session will focus on various types of protocol designs and changes, with an emphasis on adaptive designs. We will review the FDA guidance on “Adaptive Designs for Clinical Trials of Drugs and Biologics.” Taking a deeper dive into unplanned design changes and regulatory considerations, we will engage in one of the oldest thought experiments in Western philosophy, the Ship of Theseus, to address an ambiguity in clinical trial design. Here, we will consider alternative ways protocols are commonly modified, and whether those changes could be considered an entirely new clinical trial, rather than a modification. This session will also provide an educational background in trial design for professionals who haven't had as much exposure to the topic as they wish, and will include a detailed review of sections of ICH E8(R1) and ICH E6(R2), where they relate to trial design.

CEU: 1.00 ACRP

Speaker:

• Amanda Egan, Associate Clinical Research Associate, Merck

Watch a Sneak Peek into the Session Content:

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

The U.S. Food and Drug Administration's (FDA’s) recent guidance for institutional review boards on informed consent was the first update to the old “information sheets” on the topic in nearly 20 years. The Office for Human Research Protections beat FDA to the punch with new consent form requirements, but does the latest guidance mean there is a new “reasonable person” in the room? In this session, we will break down the new FDA guidance and what it means for accredited Human Research Protection Programs. Some organizations may not need to make any extensive changes, but there are differences between the FDA guidance and the expectations of the Common Rule concerning informed consent that must be considered.

CEU: 1.00 ACRP

Speaker:

• James Riddle, MCSE, CIP, CPIA, CRQM, SVP Global Review Operations, Advarra

Related Blog Content:

• New Informed Consent Expectations Should Aid Participants’ Understanding, May Catch Professionals Off Guard

Watch a Sneak Peek into the Session Content:

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Leveraging electronic tools is essential for maintaining inspection readiness in today's regulatory landscape. Paper-based methods are cumbersome and time-consuming, and they create logistical challenges in record keeping. In contrast, technology offers centralized record keeping, and electronic file storage is now both cost-effective and user-friendly. This shift is underscored by updated guidelines such as ICH E6(R3), which promotes media neutrality, flexibility, innovation, proactive quality, and robust data governance. Additionally, remote regulatory assessments, which were proven effective during the pandemic, enhance efficiency, flexibility, and global reach while reducing travel and disruption. Despite these advancements, recent feedback from regulators indicates a regression in the adoption of these technological tools. It is time for sponsors to embrace risk proportionality, which is supported by regulatory authorities, to maintain inspection readiness.

CEU: 1.00 ACRP

Speaker:

• Marc Wartenberger, CQA, CTFL, Senior Director, Security, Corporate QA & Compliance, CRIO

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

For more than a decade, multiple sources of regulatory guidance have increased their focus on risk management in clinical studies, paving the way for industry to adopt more risk-based monitoring strategies internationally. With the issuance of ICH E6(R3), an even more focused risk-based approach is expected. While Industry initially struggled to implement risk-based monitoring, moving review into central/remote scenarios as opposed to traditional onsite monitoring, we can now apply lessons learned to various indications and phases of research. We’ve come very far in tailoring systems and approaches to fit the needs of studies while still building in quality by design. Sites are important partners, but have been left out of the conversation about risk-based monitoring. Industry has fallen short in making risk-based monitoring something tangible to sites. Our goal is to bring sites a greater understanding of what sponsors/contract research organizations (CROs) are looking for, how they develop their key risk indicators, and how their ongoing monitoring and mitigation strategies impact their studies.

CEU: 1.00 ACRP

Speaker:

• Sara Croteau, Associate Director, Clinical Operations - Quality Management, Innovaderm

• Valerie Paolella, Associate Director, Clinical Trial Management, Innovaderm

Watch a Sneak Peek into the Session Content:

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Study & Site Management Journey Sponsor

Join us for an engaging, fun-filled session where staff from a large healthcare and research organization will share practical strategies for creating a workshop course series that elevates informed consent training from adequate to superior heights. Identify tactics to address gaps in your informed consent education and to navigate unique informed consent scenarios. Learn how to utilize gameplay applications and simulation activities, and how to share the knowledge of experienced clinical research staff to improve the practices of your novice clinical research workforce. Discover how to enhance your clinical research operations through empowerment of your teams to offer research opportunities to diverse clinical trial participant populations in non-ideal conditions--all while keeping your training exciting and interesting.

CEU: 1.00 ACRP

Speaker:

• Cathe Hanson, Education Coordinator - Research, Mayo Clinic

• Pam Draayer, CCRP, Education Coordinator - Research, Mayo Clinic

Watch a Sneak Peek into the Session Content:

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Conducting clinical trials on a global scale presents unique challenges, including navigating dynamic regulatory requirements and diverse landscapes. This session will examine The U.S. Food and Drug Administration's  21 CFR Part 11 from the Code of Federal Regulations and its European Union counterpart, EudraLex Annex 11, to uncover the foundational requirements for utilizing electronic records and electronic signatures in clinical trials conducted within these regions.

CEU: 1.00 ACRP

Speaker:

• Sara Saunders, MHA, CCRP, Sr. Manager, Regulatory Affairs, Florence Healthcare

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Over the next four years, the U.S. Food and Drug Administration (FDA) will phase out enforcement discretion for laboratory developed tests. These tests will be regulated as in vitro diagnostic (IVD) medical devices subject to FDA risk classification and premarket requirements for clearance/approval. Likely, there will be an increase in IVD pivotal clinical investigations. This session will look at the various IVD study designs as they relate to test users and use environments, and will highlight site considerations for readiness to support these kinds of clinical studies.

CEU: 1.00 ACRP

Speaker:

• Wendy Schroeder, Principal Strategy Consultant, Clinical, NAMSA

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Are the ICH E6(R3) guideline changes keeping you up at night? If there are burning questions and specific scenarios you need answered—or you want to hear how your industry colleagues will handle the transition from E6(R2) to E6(R3) this 60-minute live discussion is for you!

Leslie Sam and Beth Bieze will lead this interactive Q&A session where you'll have the opportunity to ask questions in an informal setting and benefit from knowledge-sharing with your ACRP peers. There will not be a prepared lecture and presentation slides, so please come with your questions!

This session will continue the conversation from ACRP's live webinar, Crack the Code: A Comparison of ICH E6(R2) and ICH E6(R3). The webinar content was designed to help clinical research, regulatory affairs, and GCP quality professionals decode the complexities of the updated guidance. Some of the questions posed by the webinar attendees which may be addressed at ACRP 2025 include:

• When will the ICH E6(R3) guideline become effective?

• How long does the industry have to update their SOPs to include E6(R3) principles and guideline updates? 

• Will clinical research professionals need to retake their GCP training?

• Is there a reason why Annex 2 was not included in the ICH E6 R3 before it was adopted?

• Does ICH E6(R3) allow the flexibility of an advanced practitioner to be the Principal Investigator?

• When will the ACRP Certification exams change to include ICH E6(R3) instead of E6(R2)?

This live discussion will be held twice on the schedule (or however you want to say this, but will be good to mention both days and times)

CEU: 1.00 ACRP

Speakers:

• Beth Bieze, MA, CCRA, ACRP-PM, FACRP, Clinical Quality Management Director, ProTrials Research Inc.

• Leslie Sam, BA, CSSBB, CQIA, President, Leslie Sam and Associates, LLC

Watch the Webinar Replay Ahead of the Q&A Session (Free Without Contact Hours):

• Crack the Code: A Comparison of ICH E6(R2) and ICH E6(R3)

Related Resource:

ACRP's Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

This session will focus on helping attendees understand what undue inducement of human research subjects is and how to reconcile this with fair compensation for participating in clinical trials. Guidance documents regarding subject payment will be examined, as will the topics of how undue inducement might occur indirectly, and the delicate ethical balance between compensation as a tool for diversification and exploitation of vulnerable subject populations.

CEU: 1.00 ACRP

Speaker:

• Steffi Leung Newell, MS, RN, OCN, CCRC, Clinical Research Nurse, Rush Medical Center

Watch a Sneak Peek into the Session Content:

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Using lessons learned from the implementation of the National Institutes of Health single institutional review board (IRB) mandate in 2018 and the Common Rule cooperative research provisions enacted in 2020, participants will explore how changes in the U.S. Food and Drug Administration (FDA) regulations requiring single IRB review, as proposed in 2022, would impact how clinical researchers get IRB approval for their studies. Building on the processes already in place nationally to have IRB review conducted by a single IRB, this session will discuss how the narrower scope of the FDA’s proposed single IRB requirements will necessitate that clinical research teams work more closely with their local IRBs and possibly the FDA prior to proposal submission. Participants will also learn more about the specific decision points required when considering whether the proposed FDA single IRB requirement applies to proposals.

CEU: 1.00 ACRP

Speaker:

• Ben Mooso, MS, CCRP, Director, Office of IRB Administration, UC San Diego

Related Resource:

The new ACRP Guidelines and Regulations Resource Center has the most relevant and up-to-date resources for all professionals whose roles involve conducting and leading clinical research. ACRP will post updates and links to content impacted by the changes to the ICH E6(R3) Good Clinical Practice Guidelines.

Watch a Sneak Peek into the Session Content: